RTTNews | Jan 9, 2022 08:24PM EST

20:24 Sunday, January 9, 2022 (RTTNews.com) - Alnylam Pharmaceuticals Inc. (ALNY) said that it expects its full year 2021 non-GAAP operating loss to be substantially improved relative to the prior year.

As of on December 31, 2021, Alnylam had preliminary cash, cash equivalents, and marketable securities of about $2.4 billion, compared to $1.9 billion at December 31, 2020.

The company reported 2021 preliminary global net product revenues of $662 million, representing a 83% annual growth compared to 2020.

Read the original article on RTTNews ( https://www.rttnews.com/3253666/alnylam-sees-fy-non-gaap-operating-loss-to-be-substantially-improved.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved